New immune-therapies are aimed at stimulating anti-tumor T-cell responses either through blockade of checkpoint inhibitors such as PD-1 and CTLA-4 or through the use of T cells with chimeric Ag receptors (CAR-T) that can respond to native Ag on tumor cells without MHC-mediated Ag presentation24–27. Here, CTLA4 is linked to neoplasm.